(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2010 (10.06.2010)

PCT

(10) International Publication Number
WO 2010/063662 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61K 31/55* (2006.01)
C07D 401/14 (2006.01) *A61P 25/22* (2006.01)
C07D 413/14 (2006.01) *A61P 25/24* (2006.01)
C07D 417/14 (2006.01) *A61P 3/04* (2006.01)

(21) International Application Number:
PCT/EP2009/066016

(22) International Filing Date:
30 November 2009 (30.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/119,118 2 December 2008 (02.12.2008) US
61/236,302 24 August 2009 (24.08.2009) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ALVARO, Giuseppe** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **AMANTINI, David** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **CASTIGLIONI, Emiliano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **PAVONE, Francesca** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agents: **LAWRENCE, Geoffrey, Mark, Prouse** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/063662 A1

(54) Title: N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0] HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF

(57) Abstract: This invention relates to *N*-{[(1*S*,4*S*,6*S*)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.